45 results about "Paclitaxel Injection" patented technology

The invention relates to a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. A molar ratio of the DSPE-PEG2000-FA to egg yolk lecithin is 0.05% to 0.15%, and a particle size of the liposome is less than 150 nm. A preparation method of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome comprises the following steps: first, preparing a DSPE-PEG2000-FA into a DSPE-PEG2000-FA micelle; second, performing incubation on the DSPE-PEG2000-FA micelle and a paclitaxel liposome together to obtain a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. Materials, which are forbidden to be used in clinical practice, are not used as crude materials in the present invention. According to the invention, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has a small particle size, and the content of the DSPE-PEG2000-FA is low; besides, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has good drug entrapment efficiency and good colloid stability. Moreover, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome can be absorbed effectively by an ovarian cancer cell having properties of sensitiveness to folic acid (+) and drug resistance, and the cytotoxicity of folic acid dependence is displayed; therefore, the efficacy of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome is stronger than that of a paclitaxel injection.

The invention discloses a taxol microemulsion drug composition and a preparation method thereof. The drug composition comprises the following active ingredients: taxol, an oil phase, a solubilizing agent, a stabilizing agent, an excipient, an acidity regulator and water for injection and is characterized in that the main grain size of taxol microemulsion ranges from 10nm to 40nm; and the parts by weight of taxol, an emulsifying agent, the oil phase and the water phase are respectively 30, 1500-3000, 100-350 and 5000-50000. The drug composition has the beneficial effects that taxol is taken as the main drug and different auxiliary materials are added to prepare microemulsion; the taxol microemulsion freeze-dried preparation prepared through freeze drying has good water solubility and stability; the clinical defect of severe allergic reaction of the taxol injection in the market is overcome; meanwhile, the preparation process is simple and is suitable for industrial mass production; and a new administration dosage form is provided for clinical application of taxol.

The invention relates to a paclitaxel injection and a preparation method of the injection: (1) 200 to 400ml of absolute alcohol and 200 to 400ml of normal saline are taken to be stirred, and 150 to 400ml of polyethylene glycol 400 is added to be evenly mixed; (2) 20 to 40g of tween-80 is added in to the mixture of (1) to be evenly mixed, and then 0.2 to 0.5g of active carbon used for injection isadded to be heated by 35 to 40 DEG C, and raw filtering is carried out and the PH value is controlled to be between 3 to 5; filtering is done and filling and sealing process is carried out; sterilization is carried out for 20 to 35 minutes at the temperature of 100 to 125 DEG C; (3) a transfusion bottle is washed and then is dried for 25 to 35 minutes the temperature of 230 to 260 DEG C, and butyl rubber plug is sterilized; (4) 0.6 to 3g of paclitaxel is taken to be added into the mixture of (2) for dissolving, and then sterilization and filtering are done; and then the solution is filled into the transfusion bottle in the sterilized environment; finally, the bottle is sealed to get the finished product. The invention can prepare safe and reliable paclitaxel injection, by adopting the method of preparing menstruum firstly and paclitaxel solution secondly, the quality of the injection is guaranteed.

The invention discloses a paclitaxel pharmaceutical composition and a preparation method thereof. The paclitaxel pharmaceutical composition consists of paclitaxel, a solubilizing agent, a stabilizing agent, an excipient, an acidity regulator and water for injection. A paclitaxel injection is prepared by adopting a freeze drying method. Compared with the prior art, the paclitaxel pharmaceutical composition disclosed by the invention is different in solubilizing process, solubilizing effect and stability. The composition does not contain an organic solvent, thus, the paclitaxel injection has the characteristics of simpler production process, more perfect appearance, shorter freeze drying time and lower equipment requirement. The composition does not contain polyoxyethylenated castor oil, so that the paclitaxel composition has no anaphylactic reaction or hemolysis or irritation. By detection, the paclitaxel injection prepared by adopting the composition and the preparation method disclosed by the invention is high in dissolvability and stability and is suitable for large-scale industrial production.

The invention relates to the technical field of anti-tumor drugs, in particular to an anti-tumor pharmaceutical composition and its preparation method and application. In order to reduce the incidence of serious adverse reactions of paclitaxel injection, improve drug safety and drug compliance of patients, the invention adopts an anti-tumor pharmaceutical composition made of refined polyoxyethylene castor oil. The comparison of impurities before and after refining polyoxyethylene castor oil showed that the content of impurities in polyoxyethylene castor oil at the retention time 0.6 and 1.2 relative to paclitaxel in the chromatogram of related substances in paclitaxel injection was significantly reduced, and the safety of polyoxyethylene castor oil was significantly improved after refining.

The invention provides a taxol composition for injection, which comprises taxol, oil for injection, an emulsifying agent and a stabilizing agent, wherein the oil for injection is selected from at least one of soybean oil, olive oil, coix seed oil, medium chain triglyceride as well as vitamin E and derivatives thereof, and the emulsifying agent is selected from at least one of egg yolk lecithin, soybean lecithin and synthetic lipid as well as amino acid. The invention also provides a preparation method of the taxol composition for injection, wherein an oil phase is prepared by the following steps: mixing and stirring taxol, the emulsifying agent and absolute ethyl alcohol until the solution is clear, then adding the oil for injection and the stabilizing agent, further stirring until the solution is clear, and volatilizing ethyl alcohol in vacuum so as to obtain the oil phase. The taxol composition for injection, provided by the invention, is high in drug loading capacity, low in lipid content and good in stability and is capable of reducing the medication risk of taxol for injection and increasing the compliance of patients.